The Best Target & The Best Chemical
The KRAS gene is an important factor that plays an on/off role in cell signaling related to cell differentiation, proliferation, and survival. When genetic mutation occurs, cells continue to proliferate or fail to control apoptosis, often leading to cancer. KRAS is a representative oncogene in which more than 30-40% of gene mutations are found in various cancers, but it has been known as an “undruggable” target until now because it is relatively difficult to develop. PHI-201 is being developed as an optimal new drug candidate by using a new drug development platform based on big data & AI.
About 25% of lung
adenocarcinoma patients have
Unmet needs about K-RAS
mutation and extending
indication even K-RAS G12C
is approved by FDA
- Development of target anticancer drugs for patients with various K-RAS mutation G12C(42%), G12V(21%), G12D(17%) etc.
- Development strategies for four binding site of K-RAS based on 3D protein structure
- Exploring the K-RAS downstream inhibitor for K-RAS site 1
- Potent in vivo efficacy and metabolic stability of K-RAS site 4 inhibitor compared to competitive drugs
- Licensing out and joint research contracts with Yuhan
Developing a pan-K-RAS inhibitor with a partner company that can be applied to various mutations in K-RAS.
Number of patients about 60,000 people (2025)
Market size $1.4B (2024) Target Market
- K-RAS mutation positive lung adenocarcinoma patient
- K-RAS mutation patients in colorectal and pancreatic cancers
Source : EvaluatePharma, KRAS inhibitor Reports / Mechanism of Action Profile / 2020 DRG Key Findings on NSCLC 2021